Pfizer is considering buying India's Agila Specialties, the injectable-medicines unit of Indian drug supplier Strides Arcolab, for a possible price of $2 billion (Rs 10,886.31 crore), Bloomberg reported on Monday.
Pfizer is doing due diligence and a deal could be reached this quarter, Bloomberg reported, citing unnamed sources.
A Pfizer spokeswoman said the company does not comment on market rumours or speculation.
Agila makes cancer treatments and antibiotics, Bloomberg said.
Copyright @ Thomson Reuters 2013